Vibrant America Clinical Laboratory

Vibrant America Clinical Laboratory

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $35M

Overview

Vibrant America is a commercial-stage clinical laboratory specializing in high-volume, automated diagnostic testing. It has positioned itself as a cost-effective provider with a rapidly expanding test menu, notably gaining FDA Emergency Use Authorization for COVID-19 serum and dried blood spot tests and achieving New York State accreditation. The company's strategy centers on technological innovation in multiplex testing and automation to drive down costs and improve turnaround times, aiming to become a leader in the autoimmune diagnostics segment while serving a national client base.

Autoimmune DiseasesInfectious Disease

Technology Platform

High-throughput automated laboratory utilizing multiplex immunoassay technology to test multiple analytes from a single sample, with capabilities for both standard serum and dried blood spot (DBS) testing. Supported by a proprietary web-based ordering and reporting portal.

Funding History

2
Total raised:$35M
Series B$25M
Series A$10M

Opportunities

The growing demand for low-cost, efficient diagnostic testing, particularly in complex areas like autoimmunity, presents a major opportunity.
Expansion of its direct-to-consumer channel and leveraging its dried blood spot technology for remote patient monitoring could open new markets and improve patient access.

Risk Factors

Key risks include intense price competition from large national labs, constant pressure from healthcare payers to reduce reimbursement rates, and the operational and regulatory complexity of maintaining compliance across all 50 states.
Technological disruption or a significant laboratory error could also threaten the business.

Competitive Landscape

Vibrant America competes directly with giant national reference laboratories (LabCorp, Quest Diagnostics) and numerous regional and specialty labs. Its strategy is to differentiate on cost, turnaround time, and focused excellence in multiplexed testing, particularly in autoimmune diagnostics, where it faces competition from specialized players like Exagen and Eurofins.